[go: up one dir, main page]

WO2002026708A1 - Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient - Google Patents

Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient Download PDF

Info

Publication number
WO2002026708A1
WO2002026708A1 PCT/JP2001/008466 JP0108466W WO0226708A1 WO 2002026708 A1 WO2002026708 A1 WO 2002026708A1 JP 0108466 W JP0108466 W JP 0108466W WO 0226708 A1 WO0226708 A1 WO 0226708A1
Authority
WO
WIPO (PCT)
Prior art keywords
nitrogen
active ingredient
same
containing compounds
ccr3 inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/008466
Other languages
French (fr)
Japanese (ja)
Inventor
Toshiya Takahashi
Takayuki Imaoka
Hiroki Tomioka
Daigo Hatakeyama
Aiko Nitta
Masayuki Kaneko
Satoko Takizawa
Yuichi Torii
Koichiro Morihira
Tatsuaki Morokata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to AU2001292276A priority Critical patent/AU2001292276A1/en
Publication of WO2002026708A1 publication Critical patent/WO2002026708A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nitrogen-containing compounds represented by the following general formula I, which are useful as CCR3 inhibitors to be used in preventing and treating allergic inflammatory diseases caused by leukergy of lymphocytes, eosinocytes, basophilic leukocytes and the like, or pharmaceutically acceptable salts thereof: Ar (CH2)l A (CH2)m B I wherein l is an integer of from 0 to 2; m is an integer of from 0 to 5; Ar represents aryl such as 2-1,2,3,4-tetrahydroisoquinolyl, phenyl or pyridyl; A represents a nitrogen-containing divalent group such as CONH-; and B represents, for example, 4-(diphenylmethyl)piperidino.
PCT/JP2001/008466 2000-09-27 2001-09-27 Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient Ceased WO2002026708A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292276A AU2001292276A1 (en) 2000-09-27 2001-09-27 Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000294355 2000-09-27
JP2000-294355 2000-09-27
JP2000313405 2000-10-13
JP2000-313405 2000-10-13

Publications (1)

Publication Number Publication Date
WO2002026708A1 true WO2002026708A1 (en) 2002-04-04

Family

ID=26600853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008466 Ceased WO2002026708A1 (en) 2000-09-27 2001-09-27 Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient

Country Status (2)

Country Link
AU (1) AU2001292276A1 (en)
WO (1) WO2002026708A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076448A1 (en) * 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag Ccr-3 receptor antagonists
WO2005040129A3 (en) * 2003-10-24 2005-06-23 Hoffmann La Roche Ccr3 receptor antagonists
WO2008123582A1 (en) 2007-04-04 2008-10-16 Kowa Company, Ltd. Tetrahydroisoquinoline compound
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516714A (en) * 1962-11-07 1968-02-05 Bayer Ag Process for preparing imidazolidine derivatives
WO1992014697A1 (en) * 1991-02-08 1992-09-03 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5780474A (en) * 1996-06-04 1998-07-14 Adir Et Compagnie 3-(piperid-4-yl)-1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds
WO2000035449A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516714A (en) * 1962-11-07 1968-02-05 Bayer Ag Process for preparing imidazolidine derivatives
WO1992014697A1 (en) * 1991-02-08 1992-09-03 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5780474A (en) * 1996-06-04 1998-07-14 Adir Et Compagnie 3-(piperid-4-yl)-1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds
WO2000035449A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076448A1 (en) * 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag Ccr-3 receptor antagonists
US7081531B2 (en) 2003-02-27 2006-07-25 Roche Palo Alto Llc Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists
WO2005040129A3 (en) * 2003-10-24 2005-06-23 Hoffmann La Roche Ccr3 receptor antagonists
JP2007509095A (en) * 2003-10-24 2007-04-12 エフ．ホフマン−ラ　ロシュ　アーゲー CCR3 receptor antagonist
WO2008123582A1 (en) 2007-04-04 2008-10-16 Kowa Company, Ltd. Tetrahydroisoquinoline compound
US8273766B2 (en) 2007-04-04 2012-09-25 Kowa Company, Ltd. Tetrahydroisoquinoline compound
JP5313881B2 (en) * 2007-04-04 2013-10-09 興和株式会社 Tetrahydroisoquinoline compounds
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Also Published As

Publication number Publication date
AU2001292276A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
DK0664126T3 (en) Inhibition of thrombin
NO20051600L (en) 1,4-disubstituted piperidine derivatives and their use as 11-betaHSD1 inhibitors
DE69432243D1 (en) 2-phenyl-3-aroylbenzothiophenes for the treatment of menstrual symptoms
NO990667L (en) Depeptide benzamidine as kinogenase inhibitor
WO1994022835A3 (en) Heterocyclic compounds as platelet aggregation inhibitors
CA2424522A1 (en) Substituted benzene derivatives or salts thereof
WO2002040474A3 (en) Heterocyclylalkyl piperidine derivatives and their use as antimicrobial agents
DK0652005T3 (en) Methods for inhibiting endometriosis
CA2040947A1 (en) Platelet-aggregation inhibitors
EA200000614A1 (en) 2,3-SUBSTITUTED INDO COMPOUNDS AS SOH-2 INHIBITORS
DK0651999T3 (en) Methods for inhibiting uterine fibrosis
DE50011034D1 (en) N-SUBSTITUTED 4-AMINOOPTERIDINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS
ATE168887T1 (en) INHIBITION OF DYSFUNCTIONAL UTERNAL BLEEDING
DK0652002T3 (en) Use of 2-phenyl-3-aroylebenzothiophenes in the manufacture of a drug for inhibiting cartilage degradation
WO2002026708A1 (en) Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
EP0277725A3 (en) 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents
AU2983792A (en) Diaminomethyleneamino substituted substituted phenyl thiazoles
ES2191763T3 (en) INHIBITOR OF DEPENDENCY / TOLERANCE DEVELOPMENT TO A NARCOTIC ANALGESIC AGENT.
CA2118425A1 (en) Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof
EP1505067A4 (en) 4,4-disubstituted piperidine derivatives having ccr3 antagonism
KR950007851A (en) Eosinophil chemotaxis inhibitor
CA2025490A1 (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
KR950703522A (en) Benzenesulfonamide derivatives and uses thereof
DK0485219T3 (en) Medicines for the prevention and treatment of circulatory organ disorders containing spiro-3-heteroazolidine compounds
WO2003014094A3 (en) Heterocyclic aryl sulphonamides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase